Intermittent maximum androgen blockade is a worthwhile option for metastatic disease: Comment
Publication
, Other
Freedland, SJ; Moul, JW
Published in: Oncology Report
September 1, 2006
Duke Scholars
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
September 1, 2006
Issue
FALL
Start / End Page
50
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Freedland, S. J., & Moul, J. W. (2006). Intermittent maximum androgen blockade is a worthwhile option for metastatic disease: Comment. Oncology Report.
Freedland, S. J., and J. W. Moul. “Intermittent maximum androgen blockade is a worthwhile option for metastatic disease: Comment.” Oncology Report, September 1, 2006.
Freedland SJ, Moul JW. Intermittent maximum androgen blockade is a worthwhile option for metastatic disease: Comment. Oncology Report. 2006. p. 50.
Freedland, S. J., and J. W. Moul. “Intermittent maximum androgen blockade is a worthwhile option for metastatic disease: Comment.” Oncology Report, no. FALL, 1 Sept. 2006, p. 50.
Freedland SJ, Moul JW. Intermittent maximum androgen blockade is a worthwhile option for metastatic disease: Comment. Oncology Report. 2006. p. 50.
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
September 1, 2006
Issue
FALL
Start / End Page
50
Related Subject Headings
- Oncology & Carcinogenesis